Table 1 Demographic and clinical characteristics of the study population

n

30

44

15

53

Age (years)

58.3 ± 5.5

72.8 ± 6.2^b

62.8 ± 6.0^a

76.4 ± 5.3^ab

Age at onset (years)

n. a.

n. a.

59.4 ± 5.6

73.6 ± 5.3^b

Females,n(%)

19 (63.3)

26 (59.1)

10 (66.7)

33 (62.3)

Education (years)

13.3 ± 3.9

11.6 ± 4.7

11.6 ± 5.0

10.5 ± 5.1

MMSE

28.9 ± 1.5

27.8 ± 1.8^b

21.5 ± 6.2^a

22.8 ± 4.2^a

CDR-SB

0.0 ± 0.0

0.0 ± 0.0

3.3 ± 2.3^a

2.9 ± 1.8^a

APOEε4 carrier,n(%)

5 (16.7)

8 (18.2)

10 (66.7)^a

26 (49.1)^a

Amyloid positivity,n(%)

1 (3.3)

6 (13.6)

15 (100)^a

53 (100)^a

Follow-up interval (months)

26.0 ± 3.6

25.1 ± 3.6

23.4 ± 1.5^a

23.0 ± 1.4^a